Medical Device Development Group
Gainesville, GA, United States
Overview
Medical Device Development Group, ( Md2G ) was founded to “commercialization” medical devices - whatever is needed from first concept to global market presence. The Md2G team has extensive medical device industry experience and has a full range of commercialization skills. These skills include product conceptualization; prototyping; developing regulatory strategy and identifying all requirements for FDA and international approvals; developing and coordinating supply chain strategy and product launch; reimbursement strategy and implementation; and, marketing, sales, and training. They also help European (and Asian) firms bring products to the USA and vice versa.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Medical
- Medical Device
Investment portfolio
- Advanced Catheter Therapies
Participated · Series A · Sep 2011
Advanced Catheter Therapies (ACT) is a Chattanooga, TN-based research and development medical device company with a portfolio of innovative catheter technologies addressing vascular disease and targeted endovascular drug delivery. Led by CEO Paul J. Fitzpatrick, the company’s lead product is the Occlusion Perfusion Catheter™ (OPC), a multi‑lumen balloon catheter designed to temporarily occlude a specific region to allow targeted delivery of therapeutic and diagnostic agents to the peripheral vasculature. The OPC is disease- and agent-agnostic, can create a localized treatment chamber and place agent circumferentially into the vasculature, and includes inflow and outflow ports for chamber evacuation, filling and flushing. ACT recently received the first limited shipment of the OPC. The device is patented and 510(k) cleared. The company intends to use new funding to bring the OPC to market for targeted applications. Advanced Catheter Therapies develops innovative catheter technologies with an initial focus on vascular disease conditions such as thrombosis, inflammation, occlusions and restenosis. The company’s pipeline centers on the patented Occlusion Perfusion Catheter (OPC), an intravascular agent delivery device. ACT has filed for 510(k) FDA approval for the OPC and is pursuing commercialization or out‑licensing of the technology. The firm is led by CEO Paul J. Fitzpatrick and operates from Chattanooga, Tennessee. The recent financing will fund further device development across ACT’s product pipeline. No operating metrics (revenue/users) were disclosed in the article. Atlanta Catheter Therapies develops a portfolio of catheter technologies aimed at treating vascular disease and preventing restenosis. Its lead product is the Occlusion Perfusion Catheter™ (OPC), an intravascular agent delivery device. The company intends to use new funds to advance and commercialize the OPC and to develop other technologies in its pipeline. It also plans to use proceeds for working capital and general corporate purposes. Atlanta Catheter Therapies is led by CEO Paul J. Fitzpatrick and was founded in 2008 by Dr. Rex Teeslink. The company is based in Chattanooga, TN.
Team
No current team members are available.